Jenburkt Pharmaceuticals Ltd

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd carries a market capitalization of 4.22B, placing it among publicly traded companies globally. Its enterprise value stands at 3.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd has 4.41M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd maintains a current ratio of 4.11, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Jenburkt Pharmaceuticals Ltd recorded 76.14M in income tax expense.

As of the close on October 23, 2026, Jenburkt Pharmaceuticals Ltd's stock has declined approximately 20.46% over the past 52 weeks. The 50-day moving average sits at 985.74, while the 200-day moving average is 1,058.19.

As of March 31, 2026, Jenburkt Pharmaceuticals Ltd holds 473.16M in cash and equivalents against 24.88M in total debt, resulting in a net debt position of -55.77M. Total book value stands at 1.97B, with working capital of 719.43M providing operational flexibility.